PMEF
SGMO

Point72 Middle East FZE’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Point72 Middle East FZE’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,709
Closed -$9.42K – 1842
2023
Q3 		$9.42K Sell
15,709
-94,318
-86% -$101K ﹤0.01% 1353
2023
Q2 		$143K Buy
+110,027
New +$150K ﹤0.01% 1139

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Point72 Middle East FZE's SGMO Position: Q4 2023 in Review

Point72 Middle East FZE sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 15,709 shares — an estimated $9.42K sold.

Point72 Middle East FZE first reported a position in SGMO in Q2 2023 and held it in 2 quarters. The position peaked at $143K in Q2 2023. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Point72 Middle East FZE reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 15,709 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $9.42K.
  • Point72 Middle East FZE first reported a position in SANGAMO THERAPEUTICS INC in Q2 2023 and held it in 2 quarters.
  • Point72 Middle East FZE's SANGAMO THERAPEUTICS INC position peaked at $143K in Q2 2023.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.